Shots:
- The P-III (ANCHOR-1: N=271, ANCHOR-2: N=257) trial assessed depemokimab + SoC vs PBO + SoC in CRSwNP pts that showed early benefits lasting over 52wks. ANCHOR data with SWIFT-1 & 2 trial data will support global filings for asthma with type 2 inflammation & CRSwNP
- Pooled analysis of 2EPs showed 0.7-point NPS decrease (-0.9 to -0.4) at 52wks. & 0.24-point VRS decrease (-0.39 to -0.08) over 49-52wks., with notable changes in rhinorrhoea & loss of smell VRS, plus Lund-Mackay CT, & SNOT-22 scores
- Analysis also showed that 74% (n=200) vs 64% (n=164) pts avoided SCS, surgery, or DMTs, while 88% (n=239) vs 83% (n=213) avoided surgery or medication by 52wks. Data was published in The Lancet
Ref: GSK | Image: GSK
Related News:- GSK Reports the China’s NMPA Acceptance of Nucala (Mepolizumab) as an Add-on Treatment for COPD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
